Tiziana Life Sciences PLC- London-based therapeutics for oncology, inflammation and infectious diseases - Says it plans phase II trials of nasal antibody treatment Foralumab for Covid-19 patients. Says Foralumab could be effective in treating new coronavirus variants from the UK, Brazil and South Africa.
Chief Medical Officer Neil Graham comments: "We are excited about this next important step in our goal to validate our drug candidate and our novel delivery system as a promising and innovative approach to immunomodulatory therapy for Covid-19 and other mutant variants. By focusing on moderating the inflammatory consequences of the SARS CoV2 virus, we hope to have a therapy that has efficacy irrespective of local viral variants."
Current stock price: 106.20 pence
Year-to-date change: up 14%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.